1921
Volume 96, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract

Postpartum women may have an altered susceptibility to and . The relationship between naturally acquired malarial immunity and susceptibility to malaria postpartum is yet to be determined. IgG levels were measured against and antigens from delivery in 201 postpartum and 201 nonpregnant controls over 12 weeks. Associations between time-varying antibody levels and time to first microscopically confirmed species-specific infection were determined by Cox regression. Associations between antibody levels and prospective risk of infection were similar in postpartum and control women. A 2-fold increase in antibody levels was associated with increased prospective risk of infection (hazard ratio [HR] range = 1.37–1.94). Antibody levels against most antigens displayed no association with prospective risk of infection (HR range = 1.02–1.05) with the exception of MSP1 antibodies that were weakly associated with prospective risk of infection (HR = 1.14 (95% confidence interval = 1.02, 1.28) per 2-fold increase in levels). Associations between antibody levels and prospective risk of infection attenuated when adjusted for documented retrospective exposure. Serology may be a useful tool to predict and monitor women at increased risk of infection postpartum, particularly in the absence of a detailed history of retrospective infections.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.16-0690
2017-05-03
2017-10-18
Loading full text...

Full text loading...

/deliver/fulltext/14761645/96/5/1197.html?itemId=/content/journals/10.4269/ajtmh.16-0690&mimeType=html&fmt=ahah

References

  1. McLean AR, Ataide R, Simpson JA, Beeson JG, Fowkes FJ, , 2015. Malaria and immunity during pregnancy and postpartum: a tale of two species. Parasitology 142: 9991015.[Crossref]
  2. Dellicour S, Guerra CA, ter Kuile FO, Snow RW, Tatem AJ, , 2010. Quantifying the number of pregnancies at risk of malaria in 2007: a demographic study. PLoS Med 7: e1000221.[Crossref]
  3. Fried M, Duffy PE, , 1996. Adherence of Plasmodium falciparum to chondroitin sulfate A in the human placenta. Science 272: 15021504.[Crossref]
  4. Salanti A, Staalsoe T, Lavstsen T, Jensen AT, Sowa MP, Arnot DE, Hviid L, Theander TG, , 2003. Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering Plasmodium falciparum involved in pregnancy-associated malaria. Mol Microbiol 49: 179191.[Crossref]
  5. Diagne N, Rogier C, Sokhna CS, Tall A, Fontenille D, Roussilhon C, Spiegel A, Trape JF, , 2000. Increased susceptibility to malaria during the early postpartum period. N Engl J Med 343: 598603.[Crossref]
  6. Ramharter M, Grobusch MP, Kiessling G, Adegnika AA, Moller U, Agnandji ST, Kramer M, Schwarz N, Kun JF, Oyakhirome S, Issifou S, Borrmann S, Lell B, Mordmuller B, Kremsner PG, , 2005. Clinical and parasitological characteristics of puerperal malaria. J Infect Dis 191: 10051009.[Crossref]
  7. Boel ME, Rijken MJ, Leenstra T, Pyae Phyo A, Pimanpanarak M, Keereecharoen NL, Proux S, Laochan N, Imwong M, Singhasivanon P, White NJ, McGready R, Nosten FH, , 2013. Malaria in the post-partum period; a prospective cohort study. PLoS One 8: e57890.[Crossref]
  8. Boel ME, Rijken MJ, Brabin BJ, Nosten F, McGready R, , 2012. The epidemiology of postpartum malaria: a systematic review. Malar J 11: 114.[Crossref]
  9. Cohen S, McGregor IA, Carrington S, , 1961. Gamma-globulin and acquired immunity to human malaria. Nature 192: 733.[Crossref]
  10. Sabchareon A, Burnouf T, Ouattara D, Attanath P, Bouharoun-Tayoun H, Chantavanich P, Foucault C, Chongsuphajaisiddhi T, Druilhe P, , 1991. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg 45: 297308.
  11. Cutts JC, Powell R, Agius PA, Beeson JG, Simpson JA, Fowkes FJ, , 2014. Immunological markers of Plasmodium vivax exposure and immunity: a systematic review and meta-analysis. BMC Med 12: 150.[Crossref]
  12. Fowkes FJI, Richards JS, Simpson JA, Beeson JG, , 2010. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: a systematic review and meta-analysis. PLoS Med 7: 120.[Crossref]
  13. Doolan DL, Dobano C, Baird JK, , 2009. Acquired immunity to malaria. Clin Microbiol Rev 22: 1336, Table of Contents.
  14. Chan JA, Howell KB, Reiling L, Ataide R, Mackintosh CL, Fowkes FJ, Petter M, Chesson JM, Langer C, Warimwe GM, Duffy MF, Rogerson SJ, Bull PC, Cowman AF, Marsh K, Beeson JG, , 2012. Targets of antibodies against Plasmodium falciparum-infected erythrocytes in malaria immunity. J Clin Invest 122: 32273238.[Crossref]
  15. Osier FHA, Fegan G, Polley SD, Murungi L, Verra F, Tetteh KKA, Lowe B, Mwangi T, Bull PC, Thomas AW, Cavanagh DR, McBride JS, Lanar DE, Mackinnon MJ, Conway DJ, Marsh K, , 2008. Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun 76: 22402248.[Crossref]
  16. Richards JS, Stanisic DI, Fowkes FJ, Tavul L, Dabod E, Thompson JK, Kumar S, Chitnis CE, Narum DL, Michon P, Siba PM, Cowman AF, Mueller I, Beeson JG, , 2010. Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia. Clin Infect Dis 51: e50e60.[Crossref]
  17. Rono J, Osier FH, Olsson D, Montgomery S, Mhoja L, Rooth I, Marsh K, Farnert A, , 2013. Breadth of anti-merozoite antibody responses is associated with the genetic diversity of asymptomatic Plasmodium falciparum infections and protection against clinical malaria. Clin Infect Dis 57: 14091416.[Crossref]
  18. Richards JS, Arumugam TU, Reiling L, Healer J, Hodder AN, Fowkes FJ, Cross N, Langer C, Takeo S, Uboldi AD, Thompson JK, Gilson PR, Coppel RL, Siba PM, King CL, Torii M, Chitnis CE, Narum DL, Mueller I, Crabb BS, Cowman AF, Tsuboi T, Beeson JG, , 2013. Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development. J Immunol 191: 795809.[Crossref]
  19. Elliott SR, Fowkes FJ, Richards JS, Reiling L, Drew DR, Beeson JG, , 2014. Research priorities for the development and implementation of serological tools for malaria surveillance. F1000Prime Rep 6: 100.[Crossref]
  20. Murungi LM, Kamuyu G, Lowe B, Bejon P, Theisen M, Kinyanjui SM, Marsh K, Osier FH, , 2013. A threshold concentration of anti-merozoite antibodies is required for protection from clinical episodes of malaria. Vaccine 31: 39363942.[Crossref]
  21. Stanisic DI, Fowkes FJ, Koinari M, Javati S, Lin E, Kiniboro B, Richards JS, Robinson LJ, Schofield L, Kazura JW, King CL, Zimmerman P, Felger I, Siba PM, Mueller I, Beeson JG, , 2015. Acquisition of antibodies against Plasmodium falciparum merozoites and malaria immunity in young children: influence of age, force of infection, and magnitude of response. Infect Immun 83: 646660.[Crossref]
  22. Bejon P, Warimwe G, Mackintosh CL, Mackinnon MJ, Kinyanjui SM, Musyoki JN, Bull PC, Marsh K, , 2009. Analysis of immunity to febrile malaria in children that distinguishes immunity from lack of exposure. Infect Immun 77: 19171923.[Crossref]
  23. McLean AR, Boel ME, McGready R, Ataide R, Drew D, Tsuboi T, Beeson JG, Nosten F, Simpson JA, Fowkes FJ, , 2016. Antibody responses to Plasmodium falciparum and Plasmodium vivax blood-stage and sporozoite antigens in the postpartum period. Sci Rep 6: 32159.[Crossref]
  24. Tjitra E, Baker J, Suprianto S, Cheng Q, Anstey NM, , 2002. Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. Antimicrob Agents Chemother 46: 39473953.[Crossref]
  25. Villegas L, McGready R, Htway M, Paw MK, Pimanpanarak M, Arunjerdja R, Viladpai-Nguen SJ, Greenwood B, White NJ, Nosten F, , 2007. Chloroquine prophylaxis against vivax malaria in pregnancy: a randomized, double-blind, placebo-controlled trial. Trop Med Int Health 12: 209218.[Crossref]
  26. Williamson EJ, Aitken Z, Lawrie J, Dharmage SC, Burgess JA, Forbes AB, , 2014. Introduction to causal diagrams for confounder selection. Respirology 19: 303311.[Crossref]
  27. Greenhouse B, Ho B, Hubbard A, Njama-Meya D, Narum DL, Lanar DE, Dutta S, Rosenthal PJ, Dorsey G, John CC, , 2011. Antibodies to Plasmodium falciparum antigens predict a higher risk of malaria but protection from symptoms once parasitemic. J Infect Dis 204: 1926.[Crossref]
  28. Bejon P, Cook J, Bergmann-Leitner E, Olotu A, Lusingu J, Mwacharo J, Vekemans J, Njuguna P, Leach A, Lievens M, Dutta S, von Seidlein L, Savarese B, Villafana T, Lemnge MM, Cohen J, Marsh K, Corran PH, Angov E, Riley EM, Drakeley CJ, , 2011. Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children. J Infect Dis 204: 918.[Crossref]
  29. Krotoski WA, Collins WE, Bray RS, Garnham PC, Cogswell FB, Gwadz RW, Killick-Kendrick R, Wolf R, Sinden R, Koontz LC, Stanfill PS, , 1982. Demonstration of hypnozoites in sporozoite-transmitted Plasmodium vivax infection. Am J Trop Med Hyg 31: 12911293.[Crossref]
  30. Robinson LJ, Wampfler R, Betuela I, Karl S, White MT, Suen CSLW, Hofmann NE, Kinboro B, Waltmann A, Brewster J, Lorry L, Tarongka N, Samol L, Silkey M, Bassat Q, Siba PM, Schofield L, Felger I, Mueller I, , 2015. Strategies for understanding and reducing the Plasmodium vivax and Plasmodium ovale hypnozoite reservoir in Papua New Guinean children: a randomised placebo-controlled trial and mathematical model. PLoS Med 12: e1001891.[Crossref]
  31. Betuela I, Rosanas-Urgell A, Kiniboro B, Stanisic DI, Samol L, de Lazzari E, Del Portillo HA, Siba P, Alonso PL, Bassat Q, Mueller I, , 2012. Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1–5 years of age. J Infect Dis 206: 17711780.[Crossref]
  32. Moody A, , 2002. Rapid diagnostic tests for malaria parasites. Clin Microbiol Rev 15: 6678.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.16-0690
Loading
/content/journals/10.4269/ajtmh.16-0690
Loading

Data & Media loading...

Supplementary Data

Supplemental Figures and Tables

  • Received : 24 Aug 2016
  • Accepted : 14 Jan 2017

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error